Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 72 entries
Sorted by: Best Match Show Resources per page
Letter: Disclosure of medical records.

British medical journal

Patterson J, Taylor JL, Barnett JW.
PMID: 1111721
Br Med J. 1975 Jan 18;1(5950):150. doi: 10.1136/bmj.1.5950.150.
Free PMC Article

No abstract available.

Cite
Patterson J, Taylor JL, Barnett JW. Letter: Disclosure of medical records. Br Med J. 1975;1(5950):150doi: 10.1136/bmj.1.5950.150.
Patterson, J., Taylor, J. L., & Barnett, J. W. (1975). Letter: Disclosure of medical records. British medical journal, 1(5950), 150. https://doi.org/10.1136/bmj.1.5950.150
Patterson, J, et al. "Letter: Disclosure of medical records." British medical journal vol. 1,5950 (1975): 150. doi: https://doi.org/10.1136/bmj.1.5950.150
Patterson J, Taylor JL, Barnett JW. Letter: Disclosure of medical records. Br Med J. 1975 Jan 18;1(5950):150. doi: 10.1136/bmj.1.5950.150. PMID: 1111721; PMCID: PMC1671933.
Copy Download .nbib Format: NLM
Connections between the Anomalous Volumetric Properties of Alcohols in Aqueous Solution and the Volume of Hydrophobic Association.

The journal of physical chemistry. B

Ashbaugh HS, Barnett JW, Saltzman A, Langrehr M, Houser H.
PMID: 28968101
J Phys Chem B. 2018 Apr 05;122(13):3242-3250. doi: 10.1021/acs.jpcb.7b08728. Epub 2017 Oct 16.

The partial molar volumes of alcohols in water exhibit a non-monotonic dependence on concentration at room temperature, initially decreasing with increasing concentration before passing through a minimum and rising to the pure liquid plateau. This anomalous behavior is associated...

Cite
Ashbaugh HS, Barnett JW, Saltzman A, et al. Connections between the Anomalous Volumetric Properties of Alcohols in Aqueous Solution and the Volume of Hydrophobic Association. J Phys Chem B. 2017;122(13):3242-3250doi: 10.1021/acs.jpcb.7b08728.
Ashbaugh, H. S., Barnett, J. W., Saltzman, A., Langrehr, M., & Houser, H. (2018). Connections between the Anomalous Volumetric Properties of Alcohols in Aqueous Solution and the Volume of Hydrophobic Association. The journal of physical chemistry. B, 122(13), 3242-3250. https://doi.org/10.1021/acs.jpcb.7b08728
Ashbaugh, Henry S, et al. "Connections between the Anomalous Volumetric Properties of Alcohols in Aqueous Solution and the Volume of Hydrophobic Association." The journal of physical chemistry. B vol. 122,13 (2018): 3242-3250. doi: https://doi.org/10.1021/acs.jpcb.7b08728
Ashbaugh HS, Barnett JW, Saltzman A, Langrehr M, Houser H. Connections between the Anomalous Volumetric Properties of Alcohols in Aqueous Solution and the Volume of Hydrophobic Association. J Phys Chem B. 2018 Apr 05;122(13):3242-3250. doi: 10.1021/acs.jpcb.7b08728. Epub 2017 Oct 16. PMID: 28968101.
Copy Download .nbib Format: NLM
Pitfalls in Interpreting mp-MRI of the Prostate: A Pictorial Review with Pathologic Correlation.

Insights into imaging

Panebianco V, Barchetti F, Barentsz J, Ciardi A, Cornud F, Futterer J, Villeirs G.
PMID: 26385690
Insights Imaging. 2015 Dec;6(6):611-30. doi: 10.1007/s13244-015-0426-9. Epub 2015 Sep 18.

OBJECTIVES: The purpose of this pictorial review is to present a wide spectrum of prostate multiparametric MRI (mp-MRI) pitfalls that may occur in clinical practice, with radiological and pathological correlation.METHODS: All examinations were performed according to ESUR Guidelines protocols.RESULTS...

Cite
Panebianco V, Barchetti F, Barentsz J, et al. Pitfalls in Interpreting mp-MRI of the Prostate: A Pictorial Review with Pathologic Correlation. Insights Imaging. 2015;6(6):611-30doi: 10.1007/s13244-015-0426-9.
Panebianco, V., Barchetti, F., Barentsz, J., Ciardi, A., Cornud, F., Futterer, J., & Villeirs, G. (2015). Pitfalls in Interpreting mp-MRI of the Prostate: A Pictorial Review with Pathologic Correlation. Insights into imaging, 6(6), 611-30. https://doi.org/10.1007/s13244-015-0426-9
Panebianco, V, et al. "Pitfalls in Interpreting mp-MRI of the Prostate: A Pictorial Review with Pathologic Correlation." Insights into imaging vol. 6,6 (2015): 611-30. doi: https://doi.org/10.1007/s13244-015-0426-9
Panebianco V, Barchetti F, Barentsz J, Ciardi A, Cornud F, Futterer J, Villeirs G. Pitfalls in Interpreting mp-MRI of the Prostate: A Pictorial Review with Pathologic Correlation. Insights Imaging. 2015 Dec;6(6):611-30. doi: 10.1007/s13244-015-0426-9. Epub 2015 Sep 18. PMID: 26385690; PMCID: PMC4656245.
Copy Download .nbib Format: NLM
Overseas electives.

Lancet (London, England)

Barnett JW.
PMID: 7901611
Lancet. 1993 Nov 20;342(8882):1303.

No abstract available.

Cite
Barnett JW. Overseas electives. Lancet. 1993;342(8882):1303
Barnett, J. W. (1993). Overseas electives. Lancet (London, England), 342(8882), 1303.
Barnett, J W. "Overseas electives." Lancet (London, England) vol. 342,8882 (1993): 1303.
Barnett JW. Overseas electives. Lancet. 1993 Nov 20;342(8882):1303. PMID: 7901611.
Copy Download .nbib Format: NLM
Magnetic resonance imaging of urinary bladder cancer.

Current opinion in urology

Barentsz JO, Witjes JA.
PMID: 17035849
Curr Opin Urol. 1998 Mar;8(2):95-103. doi: 10.1097/00042307-199803000-00005.

The treatment and prognosis of urinary bladder cancer are largely determined by the tumour stage and the presence or not of metastases. Magnetic resonance imaging and clinical staging complement each other. Magnetic resonance imaging is the most accurate technique...

Cite
Barentsz JO, Witjes JA. Magnetic resonance imaging of urinary bladder cancer. Curr Opin Urol. 1998;8(2):95-103doi: 10.1097/00042307-199803000-00005.
Barentsz, J. O., & Witjes, J. A. (1998). Magnetic resonance imaging of urinary bladder cancer. Current opinion in urology, 8(2), 95-103. https://doi.org/10.1097/00042307-199803000-00005
Barentsz, J O, and Witjes, J A. "Magnetic resonance imaging of urinary bladder cancer." Current opinion in urology vol. 8,2 (1998): 95-103. doi: https://doi.org/10.1097/00042307-199803000-00005
Barentsz JO, Witjes JA. Magnetic resonance imaging of urinary bladder cancer. Curr Opin Urol. 1998 Mar;8(2):95-103. doi: 10.1097/00042307-199803000-00005. PMID: 17035849.
Copy Download .nbib Format: NLM
Bone Morphogenic Protein Type 2 Receptor Mutation-Independent Mechanisms of Disrupted Bone Morphogenetic Protein Signaling in Idiopathic Pulmonary Arterial Hypertension.

American journal of respiratory cell and molecular biology

Barnes JW, Kucera ET, Tian L, Mellor NE, Dvorina N, Baldwin WW, Aldred MA, Farver CF, Comhair SA, Aytekin M, Dweik RA.
PMID: 27187737
Am J Respir Cell Mol Biol. 2016 Oct;55(4):564-575. doi: 10.1165/rcmb.2015-0402OC.

Altered bone morphogenic protein (BMP) signaling, independent of BMPR2 mutations, can result in idiopathic pulmonary arterial hypertension (IPAH). Glucose dysregulation can regulate multiple processes in IPAH. However, the role of glucose in BMP antagonist expression in IPAH has not...

Cite
Barnes JW, Kucera ET, Tian L, et al. Bone Morphogenic Protein Type 2 Receptor Mutation-Independent Mechanisms of Disrupted Bone Morphogenetic Protein Signaling in Idiopathic Pulmonary Arterial Hypertension. Am J Respir Cell Mol Biol. 2016;55(4):564-575doi: 10.1165/rcmb.2015-0402OC.
Barnes, J. W., Kucera, E. T., Tian, L., Mellor, N. E., Dvorina, N., Baldwin, W. W., Aldred, M. A., Farver, C. F., Comhair, S. A., Aytekin, M., & Dweik, R. A. (2016). Bone Morphogenic Protein Type 2 Receptor Mutation-Independent Mechanisms of Disrupted Bone Morphogenetic Protein Signaling in Idiopathic Pulmonary Arterial Hypertension. American journal of respiratory cell and molecular biology, 55(4), 564-575. https://doi.org/10.1165/rcmb.2015-0402OC
Barnes, Jarrod W, et al. "Bone Morphogenic Protein Type 2 Receptor Mutation-Independent Mechanisms of Disrupted Bone Morphogenetic Protein Signaling in Idiopathic Pulmonary Arterial Hypertension." American journal of respiratory cell and molecular biology vol. 55,4 (2016): 564-575. doi: https://doi.org/10.1165/rcmb.2015-0402OC
Barnes JW, Kucera ET, Tian L, Mellor NE, Dvorina N, Baldwin WW, Aldred MA, Farver CF, Comhair SA, Aytekin M, Dweik RA. Bone Morphogenic Protein Type 2 Receptor Mutation-Independent Mechanisms of Disrupted Bone Morphogenetic Protein Signaling in Idiopathic Pulmonary Arterial Hypertension. Am J Respir Cell Mol Biol. 2016 Oct;55(4):564-575. doi: 10.1165/rcmb.2015-0402OC. PMID: 27187737; PMCID: PMC5070111.
Copy Download .nbib Format: NLM
Visceral fat reduction and increase of intracellular fluid in weight loss participants on antihypertension medication.

Cardiovascular endocrinology & metabolism

Dembrowski GC, Barnes JW.
PMID: 33634253
Cardiovasc Endocrinol Metab. 2020 Jul 16;10(1):31-36. doi: 10.1097/XCE.0000000000000222. eCollection 2021 Mar.

OBJECTIVES: Complex physiological interactions between hypertension and obesity contribute to and perpetuate a heightened morbidity and mortality. With the prevalence of both hypertension and obesity reaching epidemic proportions, we asked whether antihypertensive medications affect the ability of participants to...

Cite
Dembrowski GC, Barnes JW. Visceral fat reduction and increase of intracellular fluid in weight loss participants on antihypertension medication. Cardiovasc Endocrinol Metab. 2020;10(1):31-36doi: 10.1097/XCE.0000000000000222.
Dembrowski, G. C., & Barnes, J. W. (2021). Visceral fat reduction and increase of intracellular fluid in weight loss participants on antihypertension medication. Cardiovascular endocrinology & metabolism, 10(1), 31-36. https://doi.org/10.1097/XCE.0000000000000222
Dembrowski, Gerald C, and Barnes, Jessica W. "Visceral fat reduction and increase of intracellular fluid in weight loss participants on antihypertension medication." Cardiovascular endocrinology & metabolism vol. 10,1 (2021): 31-36. doi: https://doi.org/10.1097/XCE.0000000000000222
Dembrowski GC, Barnes JW. Visceral fat reduction and increase of intracellular fluid in weight loss participants on antihypertension medication. Cardiovasc Endocrinol Metab. 2020 Jul 16;10(1):31-36. doi: 10.1097/XCE.0000000000000222. eCollection 2021 Mar. PMID: 33634253; PMCID: PMC7901822.
Copy Download .nbib Format: NLM
Clinical use of the SelectMDx urinary-biomarker test with or without mpMRI in prostate cancer diagnosis: a prospective, multicenter study in biopsy-naïve men.

Prostate cancer and prostatic diseases

Hendriks RJ, van der Leest MMG, Israël B, Hannink G, YantiSetiasti A, Cornel EB, Hulsbergen-van de Kaa CA, Klaver OS, Sedelaar JPM, Van Criekinge W, de Jong H, Mulders PFA, Crawford ED, Veltman J, Schalken JA, Barentsz JO, van Oort IM.
PMID: 33941866
Prostate Cancer Prostatic Dis. 2021 Dec;24(4):1110-1119. doi: 10.1038/s41391-021-00367-8. Epub 2021 May 03.

BACKGROUND: Risk stratification in men with suspicion of prostate cancer (PCa) requires reliable diagnostic tests, not only to identify high-grade PCa, also to minimize the overdetection of low-grade PCa, and reduction of "unnecessary" prostate MRIs and biopsies. This study...

Cite
Hendriks RJ, van der Leest MMG, Israël B, et al. Clinical use of the SelectMDx urinary-biomarker test with or without mpMRI in prostate cancer diagnosis: a prospective, multicenter study in biopsy-naïve men. Prostate Cancer Prostatic Dis. 2021;24(4):1110-1119doi: 10.1038/s41391-021-00367-8.
Hendriks, R. J., van der Leest, M. M. G., Israël, B., Hannink, G., YantiSetiasti, A., Cornel, E. B., Hulsbergen-van de Kaa, C. A., Klaver, O. S., Sedelaar, J. P. M., Van Criekinge, W., de Jong, H., Mulders, P. F. A., Crawford, E. D., Veltman, J., Schalken, J. A., Barentsz, J. O., & van Oort, I. M. (2021). Clinical use of the SelectMDx urinary-biomarker test with or without mpMRI in prostate cancer diagnosis: a prospective, multicenter study in biopsy-naïve men. Prostate cancer and prostatic diseases, 24(4), 1110-1119. https://doi.org/10.1038/s41391-021-00367-8
Hendriks, Rianne J, et al. "Clinical use of the SelectMDx urinary-biomarker test with or without mpMRI in prostate cancer diagnosis: a prospective, multicenter study in biopsy-naïve men." Prostate cancer and prostatic diseases vol. 24,4 (2021): 1110-1119. doi: https://doi.org/10.1038/s41391-021-00367-8
Hendriks RJ, van der Leest MMG, Israël B, Hannink G, YantiSetiasti A, Cornel EB, Hulsbergen-van de Kaa CA, Klaver OS, Sedelaar JPM, Van Criekinge W, de Jong H, Mulders PFA, Crawford ED, Veltman J, Schalken JA, Barentsz JO, van Oort IM. Clinical use of the SelectMDx urinary-biomarker test with or without mpMRI in prostate cancer diagnosis: a prospective, multicenter study in biopsy-naïve men. Prostate Cancer Prostatic Dis. 2021 Dec;24(4):1110-1119. doi: 10.1038/s41391-021-00367-8. Epub 2021 May 03. PMID: 33941866; PMCID: PMC8616754.
Copy Download .nbib Format: NLM
Gallium-68-somatostatin receptor PET/CT parameters as potential prognosticators for clinical time to progression after peptide receptor radionuclide therapy: a cohort study.

European journal of hybrid imaging

Ebbers SC, Heimgartner M, Barentsz MW, van Leeuwaarde RS, van Treijen MJC, Lam MMEG, Braat AJAT.
PMID: 34881405
Eur J Hybrid Imaging. 2021 Dec 09;5(1):22. doi: 10.1186/s41824-021-00116-z.

BACKGROUND: Early [METHODS: Baseline and follow-up [RESULTS: In twenty patients, median time-to-new treatment was 19.3 months (range [3.8; 36.2]). Absolute and percentual changes in both PET parameters were not associated with time-to-new treatment. A significant relation between independent baseline...

Cite
Ebbers SC, Heimgartner M, Barentsz MW, et al. Gallium-68-somatostatin receptor PET/CT parameters as potential prognosticators for clinical time to progression after peptide receptor radionuclide therapy: a cohort study. Eur J Hybrid Imaging. 2021;5(1):22doi: 10.1186/s41824-021-00116-z.
Ebbers, S. C., Heimgartner, M., Barentsz, M. W., van Leeuwaarde, R. S., van Treijen, M. J. C., Lam, M. M. E. G., & Braat, A. J. A. T. (2021). Gallium-68-somatostatin receptor PET/CT parameters as potential prognosticators for clinical time to progression after peptide receptor radionuclide therapy: a cohort study. European journal of hybrid imaging, 5(1), 22. https://doi.org/10.1186/s41824-021-00116-z
Ebbers, Sander C, et al. "Gallium-68-somatostatin receptor PET/CT parameters as potential prognosticators for clinical time to progression after peptide receptor radionuclide therapy: a cohort study." European journal of hybrid imaging vol. 5,1 (2021): 22. doi: https://doi.org/10.1186/s41824-021-00116-z
Ebbers SC, Heimgartner M, Barentsz MW, van Leeuwaarde RS, van Treijen MJC, Lam MMEG, Braat AJAT. Gallium-68-somatostatin receptor PET/CT parameters as potential prognosticators for clinical time to progression after peptide receptor radionuclide therapy: a cohort study. Eur J Hybrid Imaging. 2021 Dec 09;5(1):22. doi: 10.1186/s41824-021-00116-z. PMID: 34881405.
Copy Download .nbib Format: NLM
Utilizing a reductionist model to study host-microbe interactions in intestinal inflammation.

Microbiome

Tsou AM, Goettel JA, Bao B, Biswas A, Kang YH, Redhu NS, Peng K, Putzel GG, Saltzman J, Kelly R, Gringauz J, Barends J, Hatazaki M, Frei SM, Emani R, Huang Y, Shen Z, Fox JG, Glickman JN, Horwitz BH, Snapper SB.
PMID: 34732258
Microbiome. 2021 Nov 03;9(1):215. doi: 10.1186/s40168-021-01161-3.

BACKGROUND: The gut microbiome is altered in patients with inflammatory bowel disease, yet how these alterations contribute to intestinal inflammation is poorly understood. Murine models have demonstrated the importance of the microbiome in colitis since colitis fails to develop...

Cite
Tsou AM, Goettel JA, Bao B, et al. Utilizing a reductionist model to study host-microbe interactions in intestinal inflammation. Microbiome. 2021;9(1):215doi: 10.1186/s40168-021-01161-3.
Tsou, A. M., Goettel, J. A., Bao, B., Biswas, A., Kang, Y. H., Redhu, N. S., Peng, K., Putzel, G. G., Saltzman, J., Kelly, R., Gringauz, J., Barends, J., Hatazaki, M., Frei, S. M., Emani, R., Huang, Y., Shen, Z., Fox, J. G., Glickman, J. N., Horwitz, B. H., & Snapper, S. B. (2021). Utilizing a reductionist model to study host-microbe interactions in intestinal inflammation. Microbiome, 9(1), 215. https://doi.org/10.1186/s40168-021-01161-3
Tsou, Amy M, et al. "Utilizing a reductionist model to study host-microbe interactions in intestinal inflammation." Microbiome vol. 9,1 (2021): 215. doi: https://doi.org/10.1186/s40168-021-01161-3
Tsou AM, Goettel JA, Bao B, Biswas A, Kang YH, Redhu NS, Peng K, Putzel GG, Saltzman J, Kelly R, Gringauz J, Barends J, Hatazaki M, Frei SM, Emani R, Huang Y, Shen Z, Fox JG, Glickman JN, Horwitz BH, Snapper SB. Utilizing a reductionist model to study host-microbe interactions in intestinal inflammation. Microbiome. 2021 Nov 03;9(1):215. doi: 10.1186/s40168-021-01161-3. PMID: 34732258; PMCID: PMC8565002.
Copy Download .nbib Format: NLM
Fast Magnetic Resonance Imaging as a Viable Method for Directing the Prostate Cancer Diagnostic Pathway.

European urology oncology

Padhani AR, Schoots IG, Barentsz JO.
PMID: 34001458
Eur Urol Oncol. 2021 Dec;4(6):863-865. doi: 10.1016/j.euo.2021.04.009. Epub 2021 May 14.

No abstract available.

Cite
Padhani AR, Schoots IG, Barentsz JO. Fast Magnetic Resonance Imaging as a Viable Method for Directing the Prostate Cancer Diagnostic Pathway. Eur Urol Oncol. 2021;4(6):863-865doi: 10.1016/j.euo.2021.04.009.
Padhani, A. R., Schoots, I. G., & Barentsz, J. O. (2021). Fast Magnetic Resonance Imaging as a Viable Method for Directing the Prostate Cancer Diagnostic Pathway. European urology oncology, 4(6), 863-865. https://doi.org/10.1016/j.euo.2021.04.009
Padhani, Anwar R, et al. "Fast Magnetic Resonance Imaging as a Viable Method for Directing the Prostate Cancer Diagnostic Pathway." European urology oncology vol. 4,6 (2021): 863-865. doi: https://doi.org/10.1016/j.euo.2021.04.009
Padhani AR, Schoots IG, Barentsz JO. Fast Magnetic Resonance Imaging as a Viable Method for Directing the Prostate Cancer Diagnostic Pathway. Eur Urol Oncol. 2021 Dec;4(6):863-865. doi: 10.1016/j.euo.2021.04.009. Epub 2021 May 14. PMID: 34001458.
Copy Download .nbib Format: NLM
Risk Stratification and Artificial Intelligence in Early Magnetic Resonance Imaging-based Detection of Prostate Cancer.

European urology focus

de Rooij M, van Poppel H, Barentsz JO.
PMID: 34922897
Eur Urol Focus. 2021 Dec 15; doi: 10.1016/j.euf.2021.11.005. Epub 2021 Dec 15.

Magnetic resonance imaging (MRI) has transformed the diagnostic pathway for prostate cancer and now plays an upfront role before prostate biopsies. If a suspicious lesion is found on MRI, the subsequent biopsy can be targeted. A sharp increase is...

Cite
de Rooij M, van Poppel H, Barentsz JO. Risk Stratification and Artificial Intelligence in Early Magnetic Resonance Imaging-based Detection of Prostate Cancer. Eur Urol Focus. 2021;doi: 10.1016/j.euf.2021.11.005.
de Rooij, M., van Poppel, H., & Barentsz, J. O. (2021). Risk Stratification and Artificial Intelligence in Early Magnetic Resonance Imaging-based Detection of Prostate Cancer. European urology focus, . https://doi.org/10.1016/j.euf.2021.11.005
de Rooij, Maarten, et al. "Risk Stratification and Artificial Intelligence in Early Magnetic Resonance Imaging-based Detection of Prostate Cancer." European urology focus vol. (2021). doi: https://doi.org/10.1016/j.euf.2021.11.005
de Rooij M, van Poppel H, Barentsz JO. Risk Stratification and Artificial Intelligence in Early Magnetic Resonance Imaging-based Detection of Prostate Cancer. Eur Urol Focus. 2021 Dec 15; doi: 10.1016/j.euf.2021.11.005. Epub 2021 Dec 15. PMID: 34922897.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 72 entries